NEW YORK, March 28, 2017 -- Pomerantz LLP announces that a class action lawsuit has been filed against U.S. Concrete, Inc. (“U.S. Concrete” or the “Company”) (NASDAQ:USCR) and certain of its officers. The class action, filed in United States District Court, Northern District of Texas, and docketed under 17-cv-00266 is on behalf of a class consisting of investors who purchased or otherwise acquired U.S Concrete securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased U.S. Concrete securities between March 6, 2015 and March 23, 2017, both dates inclusive, you have until May 29, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
[Click here to join this class action]
U.S. Concrete, Inc. produces and sells ready-mixed concrete, aggregates, and concrete-related products and services for the construction industry in the United States. It operates through two segments, Ready-Mixed Concrete and Aggregate Products.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal controls over financial reporting; and (ii) as a result of the foregoing, U.S. Concrete’s public statements were materially false and misleading at all relevant times.
On March 24, 2017, U.S. Concrete filed a Current Report on Form 8-K with the Securities and Exchange Commission, announcing the resignation of the Company’s Chief Financial Officer, Joseph Tusa, and advising investors that the Company had dismissed its previous auditor, Grant Thornton LLP, and engaged Ernst & Young LLP as its new public accounting firm.
On this news, U.S. Concrete’s share price fell $5.90, or 8.84%, to close at $60.80 on March 24, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT: Robert S. Willoughby Pomerantz LLP [email protected]


Starlink Internet Remains Active in Iran Despite Nationwide Blackout
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 



